Combining Erlotinib and Cetuximab is Associated with Activity in Patients with Non Small Cell Lung Cancer (including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations

Preclinical data suggest that combined epidermal growth factor receptor (EGFR) targeting with an EGFR tyrosine kinase inhibitor and an anti-EGFR monoclonal antibody may be superior over single-agent targeting. Therefore, as part of a phase I study, we analyzed the outcome of 20 patients with non-sma...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wheler, Jennifer J., Tsimberidou, Apostolia M., Falchook, Gerald S., Zinner, Ralph G., Hong, David S., Fok, Jansina Y., Fu, Siqing, Piha-Paul, Sarina A., Naing, Aung, Kurzrock, Razelle
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4138057/
https://ncbi.nlm.nih.gov/pubmed/23963360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-12-1208
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars